Fatty-acid conjugation
also: lipidation, fatty acid acylation, albumin binding strategy, C18 conjugation, C20 conjugation
A chemical strategy that attaches a fatty-acid chain to a peptide drug, enabling reversible albumin binding that dramatically extends circulatory half-life for once-weekly dosing.
Fatty-acid conjugation — also called lipidation or acylation — is a peptide engineering strategy in which a fatty-acid chain (typically C16–C20) is covalently attached to a peptide's lysine side chain or backbone, often via a flexible linker. The attached fatty acid reversibly binds circulating albumin, the most abundant plasma protein, which acts as a depot that protects the peptide from renal filtration and enzymatic degradation, extending its functional half-life from minutes to days.
Why it matters in peptide research
The practical significance of fatty-acid conjugation is best illustrated by contrasting native GLP-1 (half-life: ~2 minutes due to DPP-IV cleavage and renal clearance) with semaglutide (half-life: ~7 days), where the only structural differences are a DPP-IV-resistant N-terminal modification and a C18 fatty-diacid chain linked via a short linker. The same albumin-binding principle is applied in tirzepatide, a dual GIP/GLP-1 receptor co-agonist that uses a C20 fatty-diacid conjugate to achieve once-weekly clinical dosing, and in retatrutide, a triple agonist (GIP/GLP-1/glucagon) in late-stage development.
Albumin binding is non-covalent and dynamic: the fatty acid chain associates and dissociates from albumin's fatty-acid binding sites continuously, maintaining a pool of free, receptor-active peptide in equilibrium with the albumin-bound depot. The fraction of free (active) peptide at any given moment is small, but constant release from the depot keeps plasma levels therapeutically relevant over a week-long dosing interval.
Beyond incretin analogues, fatty-acid conjugation has been applied to insulin (insulin degludec), peptide YY analogues, and experimental peptides across multiple therapeutic areas. The strategy is now a standard tool in peptide drug design when once-daily or once-weekly dosing is desired.
Researchers should note that fatty-acid chain length and linker chemistry substantially affect the affinity for albumin binding sites and therefore the achieved half-life. Longer chains and rigid linkers generally improve albumin affinity but can also reduce receptor potency by sterically hindering the active peptide sequence — optimisation is compound-specific.
Peptides / stacks that act on this
- Tirzepatide — dual GIP/GLP-1 receptor agonist using a C20 fatty-diacid linker to achieve once-weekly dosing through albumin-mediated half-life extension
Reading tip
Fatty-acid conjugation is sometimes confused with PEGylation, another half-life extension strategy. PEGylation adds polyethylene glycol chains, increasing hydrodynamic radius to reduce renal filtration, without albumin binding. The two strategies have different pharmacokinetic profiles and immunogenicity implications — they are not interchangeable.